Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM (NCT07209241)
Phase Ib, Open-Label Study of CART-EGFR-IL13Rฮฑ2 Cells Administered Following Lymphodepleting Chemotherapy or Prior to Surgical Resection in Patients With EGFR-Amplified Recurrent Glioblastoma
๐ฉบ Plain-English Summary (8th-Grade Level)
This is an open-label, phase 1b study to evaluate different approaches for CART-EGFR-IL13Ra2 dosing and further characterize the safety, feasibility, preliminary efficacy, and pharmacokinetics of CART-EGFR-IL13Ra2 cells in patients with EGFR-amplified glioblastoma that has recurred following prior radiotherapy.
Who can join: Review the eligibility criteria below.
Location: University of Pennsylvania โ Philadelphia, Pennsylvania
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- University of Pennsylvania โ Philadelphia, Pennsylvania
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Recurrent Glioblastoma
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma โ Duarte, California
- Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma โ La Jolla, California
- Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma โ Los Angeles, California
- Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma โ Duarte, California
- Pembrolizumab in Treating Patients With Recurrent Glioblastoma โ Houston, Texas
- IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM โ Duarte, California
Explore by condition: All Recurrent Glioblastoma clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.